Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 24 September 2009, Vol. 114, No. 13, pp. 2837-2845.
Prepublished online as a Blood First Edition Paper on July 7, 2009; DOI 10.1182/blood-2009-01-197640.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Methods and Figures
Right arrow All Versions of this Article:
blood-2009-01-197640v1
114/13/2837    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Roumenina, L. T.
Right arrow Articles by Fremeaux-Bacchi, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roumenina, L. T.
Right arrow Articles by Fremeaux-Bacchi, V.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 5, 2009
Accepted May 21, 2009

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

Lubka T. Roumenina, Mathieu Jablonski, Christophe Hue, Jacques Blouin, Jordan D. Dimitrov, Marie-Agnes Dragon-Durey, Mathieu Cayla, Wolf H. Fridman, Marie-Alice Macher, David Ribes, Luc Moulonguet, Lionel Rostaing, Simon C. Satchell, Peter W. Mathieson, Catherine Sautes-Fridman, Chantal Loirat, Catherine H. Regnier, Lise Halbwachs-Mecarelli, and Veronique Fremeaux-Bacchi*

Cordeliers Research Center, INSERM UMRS 872, Paris, France
Universite Pierre et Marie Curie (UPMC-Paris-6), Paris, France
Universite Paris Descartes, Paris, France
Assistance Publique-Hopitaux de Paris, Hopital Europeen Georges-Pompidou, Service d'Immunologie Biologique, Paris, France
Universite Paris Descartes, Patis, France
Service de Nephrologie Pediatrique, Hopital Robert-Debre, Paris, France
Unite de Nephrologie, Centre Hospitalier de Toulouse, Toulouse, France
Departement de Medecine et de Nephrologie, Hopital Ambroise Pare, Boulogne-Billancourt, France
Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, United Kingdom
INSERM U845, Hopital Necker, Paris, France

* Corresponding author; email: veronique.fremeaux-bacchi{at}egp.aphp.fr.

Complement is a major innate immune defense against pathogens, tightly regulated to prevent host tissue damage. The atypical hemolytic uremic syndrome (aHUS) is characterized by endothelial damage leading to renal failure and is highly associated with abnormal alternative pathway regulation. We characterized the functional consequences of two aHUS-associated mutations (D254G and K325N) in Factor B, a key participant in the alternative C3 convertase. Mutant proteins formed high affinity C3-binding site, leading to a hyperfunctional C3 convertase, resistant to decay by Factor H. This led to enhanced complement deposition on the surface of alternative pathway activator cells. In contrast to native Factor B, the two mutants bound to inactivated C3 and induced formation of functional C3-convertase on iC3b-coated surface. We demonstrated for the first time that Factor B mutations lead to enhanced C3-fragments deposition on quiescent and adherent human glomerular (GEnC) and umbilical vein endothelial cells (HUVEC), together with the formation of sC5b-9 complexes. These results could explain the occurrence of the disease, since excessive complement deposition on endothelial cells is a central event in the pathogenesis of aHUS. Therefore, risk factors for aHUS are not only mutations leading to loss of regulation, but also mutations, resulting in hyperactive C3 convertase.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Super factor B-gets atypical HUS
Edward M. Conway
Blood 2009 114: 2572-2574. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
E. M. Conway
Super factor B-gets atypical HUS
Blood, September 24, 2009; 114(13): 2572 - 2574.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020